SHP099, an oral SHP2 inhibitor, suppressed the progression of various malignant tumors, such as colon cancer, neuroblastoma, lung cancer and acute myeloid leukemia (AML) [104,105,106,107]. The gene discussed is PTPN11; the disease is acute myeloid leukemia.